142 related articles for article (PubMed ID: 2752132)
1. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.
Velasquez WS; Jagannath S; Tucker SL; Fuller LM; North LB; Redman JR; Swan F; Hagemeister FB; McLaughlin P; Cabanillas F
Blood; 1989 Aug; 74(2):551-7. PubMed ID: 2752132
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
3. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
4. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy.
Velasquez WS; Fuller LM; Jagannath S; Tucker SL; North LB; Hagemeister FB; McLaughlin P; Swan F; Redman JR; Rodriguez MA
Blood; 1991 Mar; 77(5):942-7. PubMed ID: 1704805
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors in low-grade lymphoma].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
Simon R; Durrleman S; Hoppe RT; Bonadonna G; Bloomfield CD; Rudders RA; Cheson BD; Berard CW
Med Pediatr Oncol; 1990; 18(2):89-96. PubMed ID: 2406556
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
11. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.
Jagannath S; Velasquez WS; Tucker SL; Fuller LM; McLaughlin PW; Manning JT; North LB; Cabanillas FC
J Clin Oncol; 1986 Jun; 4(6):859-65. PubMed ID: 2423653
[TBL] [Abstract][Full Text] [Related]
12. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
13. Risk factors in intermediate and high-grade non-Hodgkin's lymphomas of adults: a need for a new staging system.
el-Ghamrawy KA; Zawam HZ; Abdel-Azim H; Haggag M
Anticancer Drugs; 1991 Aug; 2(4):383-8. PubMed ID: 1797195
[TBL] [Abstract][Full Text] [Related]
14. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
16. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
18. EORTC trial non-Hodgkin lymphomas.
Somers R; Burgers JM; Qasim M; Van Glabbeke M; Duez N; Hayat M
Eur J Cancer Clin Oncol; 1987 Mar; 23(3):283-93. PubMed ID: 3297719
[TBL] [Abstract][Full Text] [Related]
19. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
20. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
Magrath IT; Janus C; Edwards BK; Spiegel R; Jaffe ES; Berard CW; Miliauskas J; Morris K; Barnwell R
Blood; 1984 May; 63(5):1102-11. PubMed ID: 6546890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
